Endocrine Oncology Section, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Thyroid. 2012 Mar;22(3):285-91. doi: 10.1089/thy.2011.0313. Epub 2012 Feb 3.
Thyroid cancer diagnosis in the United States has increased by 2.3-folds in the last three decades. Up to 30% of thyroid fine-needle aspiration biopsy (FNAB) results are inconclusive. Several differentially expressed microRNAs (miRNAs) have been identified as candidate diagnostic markers for thyroid nodules. We hypothesized that these differentially expressed miRNAs may improve the accuracy of FNAB in difficult to diagnose thyroid nodules.
Expression levels of four miRNAs (miR-7, -126, -374a, and let-7g) were analyzed using quantitative real-time reverse transcription-polymerase chain reaction in 95 FNAB samples as the training set. A predictor model was formulated based on the most differentially expressed miRNA (miR-7) ΔCt value and the model was applied on a separate cohort of 59 FNAB samples as the validation set.
miR-7 was the best predictor to distinguish benign from malignant thyroid FNAB samples. The other three miRNAs were co-expressed and did not significantly contribute to the predictor model. miR-7 had a sensitivity of 100%, specificity of 29%, positive predictive value (PPV) of 36%, negative predictive value (NPV) of 100%, and overall accuracy of 76% when applied to the validation set. In subgroup analysis of preoperative nondiagnostic, indeterminate, or suspicious FNAB samples, the predictor model had an overall accuracy of 37% with sensitivity of 100%, specificity of 20%, PPV of 25%, and NPV of 100%.
miR-7 may be a helpful adjunct marker to thyroid FNAB in tumor types which are inconclusive. Given the high NPV of miR-7, a patient with a benign result based on the predictor model may be followed as opposed to performing an immediate diagnostic thyroidectomy. Future prospective clinical trials evaluating its accuracy in a larger cohort are warranted to determine its clinical utility.
在过去的三十年中,美国甲状腺癌的诊断增加了 2.3 倍。多达 30%的甲状腺细针穿刺活检(FNAB)结果不确定。已经鉴定出几种差异表达的 microRNAs(miRNAs)作为甲状腺结节的候选诊断标志物。我们假设这些差异表达的 miRNAs 可能会提高 FNAB 在难以诊断的甲状腺结节中的准确性。
在 95 个 FNAB 样本的训练集中,使用实时定量逆转录聚合酶链反应分析了四种 miRNAs(miR-7、-126、-374a 和 let-7g)的表达水平。基于最差异表达的 miRNA(miR-7)ΔCt 值制定了预测模型,并将该模型应用于 59 个 FNAB 样本的独立队列作为验证集。
miR-7 是区分良性和恶性甲状腺 FNAB 样本的最佳预测因子。其他三种 miRNAs 共同表达,对预测模型没有显著贡献。当应用于验证集时,miR-7 的灵敏度为 100%,特异性为 29%,阳性预测值(PPV)为 36%,阴性预测值(NPV)为 100%,总准确率为 76%。在术前非诊断性、不确定或可疑 FNAB 样本的亚组分析中,预测模型的总准确率为 37%,灵敏度为 100%,特异性为 20%,PPV 为 25%,NPV 为 100%。
miR-7 可能是对肿瘤类型不确定的 FNAB 的有用辅助标志物。鉴于 miR-7 的高 NPV,如果基于预测模型的患者结果为良性,则可以进行随访,而不是立即进行诊断性甲状腺切除术。需要进行未来的前瞻性临床试验来评估其在更大队列中的准确性,以确定其临床效用。